Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

BACKGROUND: Starting a second-line systemic treatment for hepatocellular carcinoma (HCC) is a common situation. The only therapeutic options in France are two broad-spectrum tyrosine kinase inhibitors (TKIs), regorafenib (REG) and cabozantinib (CBZ), but no comparative real-life studies are availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhoute, Xavier, De Matharel, Marie, Mineur, Laurent, Pénaranda, Guillaume, Ouizeman, Dann, Toullec, Clemence, Tran, Albert, Castellani, Paul, Rollet, Armelle, Oules, Valérie, Perrier, Hervé, Si Ahmed, Si Nafa, Bourliere, Marc, Anty, Rodolphe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412937/
https://www.ncbi.nlm.nih.gov/pubmed/36160737
http://dx.doi.org/10.4251/wjgo.v14.i8.1510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412937/
https://www.ncbi.nlm.nih.gov/pubmed/36160737
http://dx.doi.org/10.4251/wjgo.v14.i8.1510

Ejemplares similares